Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
Clinical trial NCT03722407 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03722407
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-08-28
- Primary completion
- 2022-09-19
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.